Chronic respiratory illnesses impose a substantial economic burden on healthcare systems, patients, and society as a whole. The financial impact arises not only from direct medical costs, such as hospitalizations, long-term medication, outpatient visits, and specialized interventions, but also from indirect costs including lost productivity, absenteeism, and reduced work capacity. Economic impact of chronic respiratory illness is particularly pronounced in populations with limited access to healthcare or in regions where environmental exposures exacerbate respiratory conditions, such as air pollution or occupational hazards. Patients with conditions like chronic obstructive pulmonary disease, asthma, or interstitial lung disease often require ongoing management, including regular diagnostic testing, pulmonary rehabilitation, and lifestyle interventions, all of which contribute to cumulative costs over time. In addition, families and caregivers may face financial strain due to caregiving responsibilities and reduced income opportunities. Policymakers and healthcare providers increasingly recognize the importance of preventive strategies, early diagnosis, and cost-effective management programs to mitigate these burdens. Investment in public health measures, patient education, and community-based interventions has been shown to reduce hospital admissions and improve long-term outcomes, ultimately decreasing economic strain. Understanding the economic impact of chronic respiratory illness helps guide resource allocation, policy planning, and the design of sustainable healthcare models, ensuring that patients receive necessary care while minimizing societal costs. Addressing both clinical and economic aspects is essential for comprehensive management of chronic respiratory diseases and for promoting equitable, efficient, and sustainable healthcare systems.
Title : Novel signaling mechanisms and innovative therapeutic strategies of pulmonary hypertension
Yong Xiao Wang, Albany Medical College, United States
Title : Changing population immunity to COVID-19 in the context of infection, vaccination and emerging SARS-CoV-2 variants
Ranjan Ramasamy, ID-FISH Technology, United States
Title : Susceptibility to SARS-CoV-2 infection and nasal air conditioning ability
Ranjan Ramasamy, ID-FISH Technology, United States
Title : Comparative evaluation of DECAF and BAP 65 scores in predicting outcomes of COPD exacerbations among in patients at Vicente Sotto Memorial Medical Center
Allanys Joy Q Pino, Vicente Sotto Memorial Medical Center, Philippines
Title :
Saurabh Chattopadhyay, University of Kentucky College of Medicine, United States
Title : Personalized and precision Medicine (PPM) as a unique healthcare model through biodesign driven and inspired biotech, translational applications and pulmonology related marketing to secure the human healthcare, wellness and biosafety
Sergey Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences & InMedStar, Russian Federation